- NewsCategory：
- All Company news Industry news
common105One result
-
0919
IBio’s Collaboration with δ↔≥δSouth Africa’s AzarGen Bio ₩♦technologies Advances →∏to Next Stage
iBio, Inc. today announced that it has ente∞>&red into the initial Statement of Work ( > “SOW1”) under its Memorandum of Un☆•derstanding (“MOU”) with AzarGen Biotechno<£logies (Pty.) Ltd. (“AzarGen”).Foll'←owing iBio’s successful u"≥× se of its technologies and manufacturing capab÷£ilities to advance th" e development of AzarGen$ ’s surfactant protein therapeutic≤δα through an initial assessment↓ε of production feasibi®÷ lity, in May 2017, the tw♥≠ €o companies expanded their colλ™φlaboration by initiating the development of a ↕♦✔§plant-made rituximab for ↑®↔☆the South African market under£∞ the MOU.Pursuant to th∞ φe SOW1, iBio will manufacture research quan✘£tities of a plant-made ri©✔©>tuximab for AzarGen using iBio’s propriet✔÷•ary FastPharming™ System. Following batch product ε★∞ion, the drug product candidate will u≈♠ndergo testing via iBio CDMO’s bioanalΩλytical services.“After dem ✔&©onstrating the success of our platform throu→↕₽®gh our opening projec'♠t with AzarGen, we are now advanci ∑¥$ng to the next stage of the two companies’ §&collaboration,” commented Rober∞± t B. Kay, iBio’s Chair©≠ε✔man and CEO. “We look forward t•¶≤o helping AzarGen develop a pl≤'&∑ant-based, bio-similar rituximab produc∑↔t for the South African ma↑÷≤βrket.”“The early success in combining iBio’s and₽ ™♥ AzarGen's advanced genetic engineering and syα♥÷≥nthetic biology techniques in plants rπ₩ eally empowered us to evolve our business p∞ε'lans and product priorities to initiate developmeε₽Ω∑nt of a biosimilar version of rituximab,” said÷< ¶ Dr. Mauritz Venter, CEO of AzarGε♣₹en. “As we continue to move tow∑₹>®ard the initiation of a Ωσdvanced pre-clinical activities, we are >♣♠✔confident that iBio CDMO is ideally suited t±β®o provide us with the requisiγ≈te long-term process development×★ and cGMP manufacturing su ₽>pport. We are excited to take this impo↕♣rtant step forward in advancing this prog✘↑αram. Focusing on acce↑♦ssibility and affordability ∑εof biological medicine fo↔∏r the African continent, we look f≥↔φorward to initiating a→ dditional projects with iBio as w♦$βe progress.”Rituximab was✔λφ≠ first approved by the U.S. Food and D÷✔rug Administration in 1997 for tr ¥eatment of certain B cell non-Hodαγεgkin lymphomas. Since>±>π that time, its clinical uses have expanded 'φto encompass treatment of chronic lymphocyti♦♣c leukemia, as well as a range of ♠$γautoimmune diseases, including certain types♥± ↔ of rheumatoid arthritis. Rφ♥•δituximab has been placed on the World Heal ♦™th Organization’s List of Essent♦<¶≥ial Medicines and it was ↔±>ranked as one of the world’s top-10 sellin≤™♣★g pharmaceuticals in 2018.2019 Asia-pacific pharmΩa IP Leader Summit: http://en.zenseegroup.♣♣€★com/p/404716/ wil≈εl be held in Beijing on&≥≈nbsp;November 14-15, and will attract more→× ≥ than 500 industry experts from domestic and foreλ©<↓ign pharmaceutical companies, biotechnλ ↕ology companies, government&<'s, associations, law firms, intellectual prop®∏¶erty agents and other companies to atte ↕♦nd.Official registration and consultat®¥ion channels:Contact：AnnPhone: 021-656$ε50305Email：MarketingΩ$@zenseegroup.comhttp://www.β≤zenseegroup.com/forms/view/22113/ -
0918
Hansoh Pharma and Atomwise start strategic colβγλlaboration on AI drug discovery for multiple♣σ therapeutic areas
Major Chinese biopharmaceutical ¥↔♦∏company Hansoh Pharmaceutical Group Comp∏↑♠✔any Limited (Hanmori ≥£↓ Pharmaceutical Group Co., Lt§✔₽d., Hanso Pharmaceutical) and AI ) Atomw§≠ise, Inc., a leader in the fielλ★£d, announced the collaboration. The purpose of tδ♦♣∏he collaboration is to design and>←★• discover potential d≠✔rug candidates for a total of 11 pr÷≈ivate target proteins in multiple ther♦∞±apeutic areas.Atomwise and Hansoh PharmΩ©$a scientific teams work closelβ∑★§y together in each prog∑λram. The combination of c₩∞♣omplementary expertise and '↔←technology has the potential to dramatically €₽increase success rates and shorten schedul✔ ∞es in drug discovery and clin←∏ical development.Dr. Aifeng Lyu, Presiden®×t of Jiangsu Hansoh Pharmaceutical€ε Group Co., Ltd., a subsidiar↔$♥♥y of Hansoh Pharma, said: “Atomwi <≠se is the best partner fo÷'×r Hansoh Pharma to use AI tec€☆↓hnology to innovate and cre∏"↔$ate diverse small molecule pipelines in oncol§♥€φogy and other therapeutic areas. I ↓®εam very impressed with the team and I ←£believe that working together will p©¶rovide a special opportunity to develop↓ε first-in-class and be↓±★βst-in-class therapeutics. "Dr. Abraham Heifets,™γ CEO of Atomwise, said: “It is ≈Ω↓♠a great pleasure for us to partner "γσ with Chinese biopharmaceutic♦ al giant Hansoh Pharma. ₽¶ ↔Hansoh Pharma shares our strong co♦mmitment to innovation and our mission to inflγ₹uence patient health globally.”Atomwise's wor€Ωld-class AI platform for structure-based drug des>∑±ign leads the way in finding Ω♠←>hit compounds, selecting le£×↕ad compounds from hit compounds, and ✘♥∞γoptimizing lead compounds. Hans←↔oh Pharma will contrib"σ ute in its capacity in biologica÷€←l assays and medicinal ch≥©≠emistry, and will lead the su✘•♦×bsequent preclinical and clinical "σ✘₽development.Subject to the ter ♦ms of the collaboration, Atomwise will recε €πeive revenue based on p←ε'rivate technology fee≈♥₽λs, option exercise fees, royalties&≈, and sublicenses and s ∑↑ales of assets creat€&™¶ed under the collabora×←εtion. Based on historical average sales of sm≤←all molecule drugs, the overall pot £×ential value of this transaction for Atomwiseφ÷↑ may exceed the potential value of a hit drug ≈if all projects succeed. Hansoh Pharma≥↔α receives development and commercialization "←rights in all fields and regions.2019 A♣ "₹sia-pacific pharma IP Leader Summit: ht¥β₽♦tp://en.zenseegroup.com/p/510934/wilΩ™λl be held in Beijing &nΩ₹bsp;on November 14-15,Ω® and will attract more than 500 industry exp erts from domestic and foreign ph÷÷♣∏armaceutical companies, biotechno→≠÷logy companies, governments, associations, l≤¥σ≤aw firms, intellectua↕∞☆¥l property agents and other companies to attend.O ₹fficial registration and consultation channe™ ls:Contact：AnnPhone: 021γ★&-65650305Email：Marketing@zenseegroup.comhttp://e←π₩n.zenseegroup.com/p/510934/ -
0917
Akari Therapeutics’ Nomacopan Granted U.↔γS. Orphan Drug Designation for Bullous Pem←εphigoid
Akari Therapeutics, Plc, a biopharma≤£≈ceutical company focused on ↑₩≠innovative therapeutics to ₹♣treat orphan autoimmune and inflammato✔♦×ry diseases where the com☆δplement (C5) and/or leukotriene™∞ (LTB4) systems are implicated, today a"≤nnounced that the U.S. Food and D✘®₩↓rug Administration (FDA) has granΩ←ted orphan drug designation for nomacopan f↔βor the treatment of bullous pemβ™₩•phigoid (BP).“BP, a severe blistering 'skin condition with no approved treatment♥ §•s, is an exciting therapeutic target¥♥π for our lead drug candidate, noΩ αmacopan. It is also a disease of ∏∏≤↕increasing prevalence ✘÷φ≤due to an aging population and improving★™σ→ diagnosis,” said Clive Richard↔ ®son, Chief Executive Officer of Akari Th ✘erapeutics. “Orphan drug designation for ♠•✔✘nomacopan is a major step forward for th✔γ≈γe program, positionin$€↔¥g nomacopan for eligi÷"↕→bility for an additional seven years of market←< ing exclusivity in BP if nomacopan is ≥π₹approved by the FDA. This news is in addit♣→♦ion to the recent orphan₹€ drug designation received for our HSCT-TMA pr♣£✔ogram.”The Company plans to relea&£se new safety and efficacy data €from an ongoing Phase II trial ↔≈with nomacopan in patients ♣× with BP at an oral presentation by D₹₹₽r. Christian Sadik at the 28th European Academ<y of Dermatology and Venereo™↑logy (EADV) Congress on October 10, 201 ←≥9. In August, the Company announced new data deγ∞→monstrating the synergistic benefits of nomacopan€$↑’s dual C5 and LTB4 inhibitory activity in £±®pemphigoid disease, generated by Dr. Chr≠>♠∏istian Sadik’s group at University←☆ of Lubeck, Germany, ↔and published in the" August 2019 edition of JCI InsiΩ≥&ght [link].Orphan drug designation by the σ©∞FDA is granted to promote the developmenβ★t of drugs that target conditions aff♠Ωecting 200,000 or fewer U.S. patients annually↓♠ and that are expected to provide§↑ significant therapeutic advantage ov↓$≈er existing treatments. Orphan designatio♠★n qualifies Akari for vaβ↔®≈rious benefits, including seven years of market £ §exclusivity following marketing approval,β¶ tax credits on U.S. clinica∑≠'∑l trials, eligibility for orphan ↔≤ drug grants, and a waiver of cer•≥tain administrative fees.2019 A↔δπ>sia-pacific pharma IP Le∞×≠ader Summit:http://en.zenseegroup.com/p/51093±₽♦>4/will be held in Beijing on&nb πsp;November 14-15, and will attract more thσαγan 500 industry experts from dome♦←"stic and foreign pharmaceutical companieφπs, biotechnology companie≈☆s, governments, associa±<tions, law firms, inα→♠tellectual property agents and other compan÷≈©♣ies to attend.Official registration and c≈Ω"onsultation channels:→≠♠Contact：AnnPhone: 021-65650305E→♠→ mail：Marketing@zenseegroup.comhttp://en.zenseegr&<®oup.com/p/510934/ -
0916
Hansen Pharmaceuticals and™≈ Atomwise Launch Strategic Collaboration o™∞n Artificial Intelligence Drug Discove® ry in Multiple Therapeutic Areas
China's leading biopharma✔≤≈ceutical company Hansoh Pharmaceutical Group Com↑πpany Limited (" Hansen$≥β☆ Pharmaceutical ") and drug discoveφ€ry artificial intelligence (AI) Atomwise, Inc→". (" Atomwise ") , a leader in the field, announ✔•ced a collaborative design and discovery of €σ₽potential drug candidates for up to ®™≤→11 unexposed target proteins in π±☆×a variety of therapeutic ∏ areas.Atomwise and Ha×λ₹nsen Pharmaceutical's scientific team w₩♠₽ill work closely together in these proπ←γjects. The combination of complementary exper♥♣σ₹tise and technology is expected to s★§ignificantly increase succe™≠ss and reduce timelines for drug discovery and ∏→λclinical development.Dr. Lu Aifeng, Pre>>☆ sident of Jiangsu Hansoh Pharmaceutical G®♦roup Co., Ltd., said: Hansen Pharmaceut&σ ical is committed to using AI technol →ogy to innovate and develop div♥ ✔ erse small molecules in the fie×≈ld of cancer and other therapeutics. Atomwise is↑& the right partner for Hansen Pharmaceuticals. WπΩ"εe are very impressed wi× th Atomwise's AI platform, ₹♠✘capabilities and team. We believe that♣ ™ the two companies will have an excellen•π≥σt opportunity to develop similar →>÷πand best-in-class th¥λ±•erapeutic drugs. ."Dr. Abraham Heifets, CEO o≈≥f Atomwise, said: "We are very excited to work wi≈§♦th Hansen Pharmaceutical, Chi✔∞ na's leading biopharmaceutical ¶→"company. Hansen Pharmaceuticals and↔±φ we all have strong commitment to innovatio ≈∏©n and a common mission to©♦ influence the health of patients worlα∑dwide. ."The world-class AI σ™ platform for Atomwise structured drug desi ₽™gn will guide efforts in hit discovery•₹, accidental discovery to hit-to-lead s←"↕εelection, and optimization of lead compounds★≈γ. Hansen Pharmaceuticals is commi$™₩ tted to biological test>δ§ing and pharmaceutical ©βchemistry, as well as leading subseq®✘₽uent preclinical and clinical development activ∏ ₹∑ities.Under the terms of the partεβ≠€nership, Atomwise will receive "•®&undisclosed technology royalties, optional royβ™→alties, royalties, and subcontracti"φ←"ng authorizations or revenuλ←e generated from the sale of Ωγ♠the derivative asset↓≤>s. Based on the historical average turn¶÷<≥over of small molecule drugs, the ₩↕ potential total value of all successful pro"₩jects with Atomwise's transacΩ✔≤↑tion may exceed potential selling drugs. " ×Hanson Pharmaceuticals wi•Ωll receive development and∏✔♥★ commercialization rights in al≤π∏l fields and geographies.2019 Asia-p↓βacific pharma IP Leader Summit: http://≥↕♥λen.zenseegroup.com/p/510934/will be hel₩♣'©d in Beijing &nbs©≈"p;on November 14-15, and will a♣→ ttract more than 500 industry ex¥¥perts from domestic and foreign pharmaceu¶≤tical companies, biotechnology c∞ε↑ompanies, governments, associ"∞ations, law firms, int★★ellectual property agents and other companieδ±s to attend.Official registration a≠↓nd consultation channels>≠®:Contact：AnnPhone: 021-65650305Email：M"¥arketing@zenseegroup.comhttp://en.zenseegro↕γup.com/p/510934/ -
0912
I-Mab Biopharma and Junshi Biosciences Announ☆✘±ce Collaboration to Evaluate→ ∞ TJD5 in Combination with Toripalimab
WEDNESDAY, SEPTEMBER 11, ↕Ω δ2019I-Mab Biopharma (I-Mab), a Chin≤"a and U.S.-based clinical stage bioph <φarmaceutical company ex™₩÷clusively focused on t★↑• he discovery and development of potential firs ←↑t-in-class and best-in-class bio₹✔£©logics in immuno-oncology and autoimmune ♥ε>diseases announces the ★signing of a collaboration agreement wit←¶•≈h Shanghai Junshi Biosciences Co., Ltd (Junsσhi Biosciences), an in↔&novation-driven biopharmaceutical company to e©☆±•valuate the combination therapy of I-Ma§÷<→b's TJD5, a proprietary innovative CD73 α"λantibody with Junshi Biosciences' Toripalim∑&ab (Trade name: Tuoyi), a recombinant humanized a₽§nti-PD-1 monoclonal antibody in patien∞∏>ts with cancers in Ch®✔♠ina.Dr. Jingwu Zang, Foun'λβder and Chairman of I-Ma∑λb, commented, "TJD5 is an innovε≠ative CD73 antibody with best-in-class p±Ω★otential that has ent∑λered into Phase I trial in th•♥∏e US. We are very pleased toφ® collaborate with Junshi to explore th<e clinical synergies with Toripalimab whichΩ★ is an innovative drug with distinctive treat ≠λment advantages. We ar£↓e looking forward to bringing more clinical benef♣✘its to patients across various cancer t≈÷÷ypes."Dr. Ning Li, CEO o§♥≤'f Junshi Biosciences, commented, "As✔ ₹ an anti multi-tumor drug, tor∑"§ipalimab has shown good safety and effi¥∞×cacy in clinical trials w♠"ith mono and combination therapy. We believe, ♣αthrough the cooperation with I-Mab, we coul$™✔d continue to explore the combination poteσ§♠§ntial of toripalimab and i♥€↕nnovative drugs to improve the outcomes of immu&÷§¶ne-oncology therapy, lightening hope for more pπ≥> atients.2019 Asia-pa₽☆≈∏cific pharma IP Leader Summit: http://en.zen±•₩seegroup.com/p/510934/ will be held in £ Beijing on £↓;November 14-15, and will attract more £♣≈♠than 500 industry experts f₹₩₽rom domestic and foreiφ←gn pharmaceutical compaβnies, biotechnology companies÷♦ , governments, associations, law firms, i ¥♠ntellectual property agents and other compan÷×✔ies to attend.Official registra↑αtion and consultation channels:Contact：AnnPhone♠₽♠: 021-65650305Email：•♠Marketing@zenseegroup.comhttp://en.©↕zenseegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016